EP0322854A1 - Purinyl cyclobutanes - Google Patents
Purinyl cyclobutanes Download PDFInfo
- Publication number
- EP0322854A1 EP0322854A1 EP88121712A EP88121712A EP0322854A1 EP 0322854 A1 EP0322854 A1 EP 0322854A1 EP 88121712 A EP88121712 A EP 88121712A EP 88121712 A EP88121712 A EP 88121712A EP 0322854 A1 EP0322854 A1 EP 0322854A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- compound
- formula
- hydrogen
- accordance
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- NYNWDJSODKKDFE-UHFFFAOYSA-N 2-cyclobutyl-7h-purine Chemical class C1CCC1C1=NC=C(NC=N2)C2=N1 NYNWDJSODKKDFE-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 265
- 239000001257 hydrogen Substances 0.000 claims abstract description 74
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 74
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 46
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 230000000840 anti-viral effect Effects 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 69
- 125000006239 protecting group Chemical group 0.000 claims description 57
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 52
- 239000000203 mixture Substances 0.000 claims description 44
- -1 chloro, bromo, iodo, hydroxy Chemical group 0.000 claims description 42
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 41
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 36
- 150000002431 hydrogen Chemical class 0.000 claims description 23
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 21
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 20
- 125000001153 fluoro group Chemical group F* 0.000 claims description 19
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 15
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 12
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 claims description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims description 10
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 125000001246 bromo group Chemical group Br* 0.000 claims description 10
- 125000002346 iodo group Chemical group I* 0.000 claims description 10
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 5
- JGJLWPGRMCADHB-UHFFFAOYSA-N hypobromite Inorganic materials Br[O-] JGJLWPGRMCADHB-UHFFFAOYSA-N 0.000 claims description 5
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 claims description 4
- 229910018828 PO3H2 Inorganic materials 0.000 claims description 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 4
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 claims description 3
- 102000055025 Adenosine deaminases Human genes 0.000 claims description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims description 3
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 3
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims description 3
- 235000003270 potassium fluoride Nutrition 0.000 claims description 3
- 239000011698 potassium fluoride Substances 0.000 claims description 3
- 235000013024 sodium fluoride Nutrition 0.000 claims description 3
- 239000011775 sodium fluoride Substances 0.000 claims description 3
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Inorganic materials [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 claims description 3
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 claims description 3
- 241000271566 Aves Species 0.000 claims description 2
- QZRGKCOWNLSUDK-UHFFFAOYSA-N Iodochlorine Chemical compound ICl QZRGKCOWNLSUDK-UHFFFAOYSA-N 0.000 claims description 2
- 239000007868 Raney catalyst Substances 0.000 claims description 2
- 229910000564 Raney nickel Inorganic materials 0.000 claims description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 235000003891 ferrous sulphate Nutrition 0.000 claims description 2
- 239000011790 ferrous sulphate Substances 0.000 claims description 2
- 239000001632 sodium acetate Substances 0.000 claims description 2
- 235000017281 sodium acetate Nutrition 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 150000004703 alkoxides Chemical class 0.000 claims 1
- 230000000382 dechlorinating effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000376 reactant Substances 0.000 claims 1
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 abstract description 8
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 56
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 40
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
- 238000006243 chemical reaction Methods 0.000 description 32
- 239000007787 solid Substances 0.000 description 24
- 239000000047 product Substances 0.000 description 21
- 125000002252 acyl group Chemical group 0.000 description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 16
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 15
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 15
- 238000010511 deprotection reaction Methods 0.000 description 15
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 14
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 12
- 0 C[N+]*(*[N+](C)N)C(C1)C1*=C Chemical compound C[N+]*(*[N+](C)N)C(C1)C1*=C 0.000 description 12
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 11
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 11
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 239000003039 volatile agent Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 239000011260 aqueous acid Substances 0.000 description 9
- 229910052708 sodium Inorganic materials 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- 229910000104 sodium hydride Inorganic materials 0.000 description 9
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000012312 sodium hydride Substances 0.000 description 8
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- YETIMGFGOCVNQL-UHFFFAOYSA-N (3-chlorocyclobutyl)methanol Chemical compound OCC1CC(Cl)C1 YETIMGFGOCVNQL-UHFFFAOYSA-N 0.000 description 7
- 239000012300 argon atmosphere Substances 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 239000003054 catalyst Substances 0.000 description 7
- 150000002118 epoxides Chemical class 0.000 description 7
- 238000007327 hydrogenolysis reaction Methods 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 6
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 6
- 235000011181 potassium carbonates Nutrition 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- VFTFKUDGYRBSAL-UHFFFAOYSA-N 15-crown-5 Chemical compound C1COCCOCCOCCOCCO1 VFTFKUDGYRBSAL-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- RLBJUFJRBIEEPV-UHFFFAOYSA-N cyclobut-2-en-1-ylmethoxymethylbenzene Chemical compound C1C=CC1COCC1=CC=CC=C1 RLBJUFJRBIEEPV-UHFFFAOYSA-N 0.000 description 4
- 238000003682 fluorination reaction Methods 0.000 description 4
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 4
- 229910000105 potassium hydride Inorganic materials 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 241000450599 DNA viruses Species 0.000 description 3
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 3
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 3
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 241000700618 Vaccinia virus Species 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- RUYNTLUDGSFPFZ-UHFFFAOYSA-N cyclobutanol Chemical compound OC1[CH]CC1 RUYNTLUDGSFPFZ-UHFFFAOYSA-N 0.000 description 3
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 3
- 239000012259 ether extract Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 239000003880 polar aprotic solvent Substances 0.000 description 3
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 3
- 235000019345 sodium thiosulphate Nutrition 0.000 description 3
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- RTTWFZUEZTWOJF-UHFFFAOYSA-N (3-chlorocyclobutyl)methoxymethylbenzene Chemical compound C1C(Cl)CC1COCC1=CC=CC=C1 RTTWFZUEZTWOJF-UHFFFAOYSA-N 0.000 description 2
- LULAYUGMBFYYEX-UHFFFAOYSA-N 3-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 101710163092 D-lysergyl-peptide-synthetase subunit 1 Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 238000000023 Kugelrohr distillation Methods 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- KRWMERLEINMZFT-UHFFFAOYSA-N O6-benzylguanine Chemical compound C=12NC=NC2=NC(N)=NC=1OCC1=CC=CC=C1 KRWMERLEINMZFT-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N anhydrous n-heptane Natural products CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000006735 epoxidation reaction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
- 239000011736 potassium bicarbonate Substances 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- SMBZJSVIKJMSFP-UHFFFAOYSA-N trifluoromethyl hypofluorite Chemical compound FOC(F)(F)F SMBZJSVIKJMSFP-UHFFFAOYSA-N 0.000 description 2
- JNGWKCBNKZBPLB-UUOKFMHZSA-N (2r,3r,4s,5r)-2-(4-aminoimidazo[4,5-d]triazin-7-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NN=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JNGWKCBNKZBPLB-UUOKFMHZSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- LENAVORGWBTPJR-UHFFFAOYSA-N (5-pyridin-3-ylfuran-2-yl)methanamine Chemical compound O1C(CN)=CC=C1C1=CC=CN=C1 LENAVORGWBTPJR-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 1
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 101100313763 Arabidopsis thaliana TIM22-2 gene Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- FPWIOGLOVQWMPG-DAXSKMNVSA-N C/C(/CN)=N/[IH]C Chemical compound C/C(/CN)=N/[IH]C FPWIOGLOVQWMPG-DAXSKMNVSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- COUCDSASGHQUQI-UHFFFAOYSA-N CC(C)CC(NC[N+](C#CN)=C)=C Chemical compound CC(C)CC(NC[N+](C#CN)=C)=C COUCDSASGHQUQI-UHFFFAOYSA-N 0.000 description 1
- LEKHNBIGVZMDKH-UHFFFAOYSA-N CN1C2NNN=CC2NC1 Chemical compound CN1C2NNN=CC2NC1 LEKHNBIGVZMDKH-UHFFFAOYSA-N 0.000 description 1
- LVHXDOHAMTWNDA-UHFFFAOYSA-N CN[O](C)(CN)N Chemical compound CN[O](C)(CN)N LVHXDOHAMTWNDA-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000713730 Equine infectious anemia virus Species 0.000 description 1
- 241000714165 Feline leukemia virus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 229910052925 anhydrite Inorganic materials 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- VZGDMQKNWNREIO-UHFFFAOYSA-N carbon tetrachloride Substances ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- RCTYPNKXASFOBE-UHFFFAOYSA-M chloromercury Chemical group [Hg]Cl RCTYPNKXASFOBE-UHFFFAOYSA-M 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- FDLDWKIEWAWOSL-UHFFFAOYSA-N ethyl acetate;2-methylpentane Chemical compound CCCC(C)C.CCOC(C)=O FDLDWKIEWAWOSL-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- WOMSTXBCVBQGKV-UHFFFAOYSA-N methanol;palladium Chemical compound [Pd].OC WOMSTXBCVBQGKV-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 208000005871 monkeypox Diseases 0.000 description 1
- 229940111688 monobasic potassium phosphate Drugs 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 208000009091 myxoma Diseases 0.000 description 1
- WHQSYGRFZMUQGQ-UHFFFAOYSA-N n,n-dimethylformamide;hydrate Chemical compound O.CN(C)C=O WHQSYGRFZMUQGQ-UHFFFAOYSA-N 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- RARSHUDCJQSEFJ-UHFFFAOYSA-N p-Hydroxypropiophenone Chemical compound CCC(=O)C1=CC=C(O)C=C1 RARSHUDCJQSEFJ-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 1
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 125000005208 trialkylammonium group Chemical group 0.000 description 1
- VPAYJEUHKVESSD-UHFFFAOYSA-N trifluoroiodomethane Chemical compound FC(F)(F)I VPAYJEUHKVESSD-UHFFFAOYSA-N 0.000 description 1
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
- C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
- C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- Antiviral activity is exhibited by compounds having the formula and pharmaceutically acceptable salts thereof.
- the symbols are as defined below.
- alkyl refers to both straight and branched chain groups. Those groups having 1 to 10 carbons are preferred.
- substituted alkyl refers to alkyl groups having one or more substituents. Preferred substituents are halogen, amino, azido, hydroxy, cyano, trialkylammonium (wherein each alkyl group has 1 to 6 carbons), alkoxy of 1 to 6 carbons, aryl and carboxy.
- aryl refers to phenyl and phenyl substituted with one, two or three substituents.
- Preferred substituents are alkyl of 1 to 6 carbons, alkoxy or 1 to 6 carbons, halogen, trifluoromethyl, amino, alkylamino, dialkylamino, nitro, cyano, alkanoyloxy of 2 to 11 carbons, carboxy, carbamoyl and hydroxy.
- the compounds of formula 1, and the pharmaceutically acceptable salts thereof are antivital agents that can be used to treat viral infection in mammalian species such as domesticated animals (e.g., dogs, cats, horses and the like) and humans, and avian species (e.g., chickens and turkeys).
- the compounds of formula 1 wherein R 1 is and R 2 and R 3 are independently hydrogen, -P0 3 H 2 , or are effective against herpes simplex virus 1 and 2, varicella-zoster virus, cytomegalovirus and vaccinia virus. They may also be effective against a variety of retroviruses and other DNA viruses.
- Exemplary DNA viruses in addition to those named above include other herpes viruses (e.g., Epstein-Barr virus, pseudorabies virus, and the like), other. poxviruses (e.g., monkey pox and myxoma), papovaviruses (e.g., the papilloma viruses), hepatitis B virus, and adenoviruses.
- Exemplary retroviruses are those effecting man, such as human immunodeficiency viruses (HIV) and human T-cell lymphotropic viruses I and II (HTLV-I and II), and those affecting other animals, such as feline leukemia virus, murine leukemia virus, and equine infectious anemia virus.
- R 1 All of the other compounds in Formula 1 with the exception of wherein R 1 is are believed to be active against herpes simplex virus 1 and 2, varicella-zoster virus, cytomegalo-virus, and vaccinia virus. They are also believed to be active against the retroviruses and other DNA viruses described above.
- the compounds of Formula 1 wherein R 1 is are believed to be active against the various DNA and retroviruses described above with the exception of herpes simplex virus 1 and 2, varicella-zoster virus, cytomegalovirus, and vaccinia virus.
- the compounds may be administered orally or parenterally in an amount effective to treat the infection.
- the dosage will, of course, depend on the severity of the infection, but will likely be in the range of about 1.0 to 30 mg/kg of body weight.
- compositions may be applied to the infected part of the body of the patient topically as an ointment, cream, aerosol, gel, powder, lotion, suspension or solution (e.g., as eye drops).
- concentration of the compound in the vehicle will, or course, depend on the severity of the infection, but will likely be in the range of about 0.1 to 7% by weight.
- the compounds of this invention can be prepared from the known chemical compound 1-chloro-3-(hydroxymethyl)cyclobutane, which is a racemic mixture of cis and trans diasteriomers. Its hydroxymethyl group is first protected using, for example, a silyl containing group (e.g., a hindered trisubstituted silyl such as t-butyldiphenylsilyl, di-t-butylmethylsilyl, or triisopropylsilyl), trityl, substituted trityl (e.g., 4-monomethoxytrityl or 4,4 -dimethoxytrityi), or benzyl protecting group.
- the protection reaction yields a compound of the formula wherein the protecting group "P" serves to protect the hydroxyl group from involvement in subsequent reactions.
- This protected cyclobutane is a mixture of cis and trans isomers.
- Protection with a benzyl group can be accomplished by treating 1-chloro-3-(hydroxymethyl) cyclobutane with sodium hydride in the presence of benzyl bromide in a polar aprotic solvent such as dimethylformamide, dimethylsulfoxide or tetrahydrofuran. Protection with a t-butyldiphenylsilyl group can be accomplished by treating a dimethylformamide solution of 1-chloro-3-(hydroxymethyl)cyclobutane with t-butyldiphenylsilyl chloride in the presence of imidazole.
- Protection with a trityl or substituted trityl group can be accomplished by (i) treating a pyridine solution of 1-chloro-3-(hydroxymethyl)cyclobutane with trityl chloride or substituted trityl chloride, (ii) treating a dimethylformamide solution of 1-chloro-3-(hydroxy methyl)cyclobutane with trityl chloride or substituted trityl chloride in the presence 4-N,N-dimethylaminopyridine or (iii) treating a dichloromethane solution of 1-chloro-3-(hydroxymethyl)cyclobutane with trityl chloride or substituted trityl chloride in the presence of triethylamine.
- Epoxidation of a compound of formula 3 using a peracid, such as m-chloroperoxybenzoic acid yields the corresponding compound having the formula as a racemic mixture of cis and trans diastereomers. Separation of the diastereomers using conventional methodology provides the desired trans stereoisomer having the formula as a racemic mixture.
- preferential formation of the trans epoxide can be achieved by treating a methanol solution of a compound of formula 3 with benzonitrile/30% hydrogen peroxide in the presence of a buffer (e.g., potassium bicarbonate or monobasic potassium phosphate/sodium hydroxide).
- a buffer e.g., potassium bicarbonate or monobasic potassium phosphate/sodium hydroxide
- nucleophilic substitution on the epoxide of a compound of formula 5 using a compound of formula in the presence of a base such as potassium carbonate, sodium hydride, or potassium hydride in an aprotic polar solvent such as dimethylformamide, dimethyl sulfoxide, or sulfolane (tetra methylene sulfone) yields the corresponding compound of formula
- reaction can be run in the presence of a metal chelating catalyst such as 18-crown-6 (1,4,7,10,13,16-hexaoxacyclooctadecane) or 15-crown-5 (1,4,7,10,13-pentaoxacyclopentadecane).
- a metal chelating catalyst such as 18-crown-6 (1,4,7,10,13,16-hexaoxacyclooctadecane) or 15-crown-5 (1,4,7,10,13-pentaoxacyclopentadecane).
- Removal of the protecting group P from a compound of formula 7 yields a compound of formula 1 wherein R 1 is and R 2 and R 3 are hydrogen.
- the protecting group P is benzyl
- the group can be removed by treatment with boron trichloride in dichloromethane.
- the protecting group P is a silyl protecting group
- removal of the group can be accomplished using fluoride ion (e.g., tetrabutylammonium fluoride in tetrahydrofuran).
- fluoride ion e.g., tetrabutylammonium fluoride in tetrahydrofuran
- the protecting group P is a trityl or substituted trityl group
- removal of the group can be accomplished using aqueous acid (e.g., aqueous acetic acid) according to methods known in the art.
- simultaneous removal of the P group and the purine 0-benzyl group can be effected by using sodium in liquid ammonia, by hydrogenolysis (e.g., palladium hydroxide on carbon, cyclohexene, and ethanol), or by using boron trichloride in dichloromethane.
- the purine O-benzyl group can be removed first using aqueous alcoholic mineral acid followed by removal of the P group using, for example, sodium in liquid ammonia or hydrogenolysis.
- the protecting group P is a silyl protecting group
- removal of the P group can be accomplished using fluoride ion (e.g., tetrabutylammonium fluoride in tetrahydrofuran).
- fluoride ion e.g., tetrabutylammonium fluoride in tetrahydrofuran
- the purine O-benzyl group can then be removed with aqueous alcoholic mineral acid, by hydrogeneolysis, or with sodium in liquid ammonia.
- the purine O-benzyl group can be deprotected first by hydrogenolysis followed by removal of the silyl P group using fluoride ion.
- the protecting group P is a trityl or substituted trityl group
- removal of the P group and the purine O-benzyl group can be accomplished simultaneously using aqueous/alcoholic mineral acid.
- this compound of formula 1 can be prepared from a compound of formula 7.
- the protecting group P in 7 is benzyl
- removal of the P group can be effected first by treatment with boron trichloride, and then the chloro group can be hydrolized using aqueous acid (e.g., aqueous hydrochloric acid).
- the chloro group can be hydrolized first followed by removal of the benzyl group.
- the protecting group P in 7 is silyl
- the protecting group can be removed by treatment with fluoride ion, and then the chloro group can be hydrolized.
- the protecting group P in 7 is a trityl or substituted trityl group
- the protecting group can be removed and the chloro group can be simultaneously hydrolized using aqueous acid.
- this compound of formula 1 can be prepared by removal of the protecting group P from a compound of formula 7 followed by treatment with adenosine deaminase by methods known in the art (e.g., M. J. Robins and P. W Hatfield, Can. J. Chem., 60, 547 (1982)).
- a compound of formula 1 wherein Ri is and R 2 and R 3 are hydrogen can be prepared from a compound of formula 7.
- the P group in 7 is benzyl
- deprotection and reduction of the chloro group can be accomplished simultaneously by hydrogenation (e.g., ammonium formate and palladium on carbon in methanol; palladium hdyroxide on carbon and cyclohexene in ethanol; or palladium on carbon, hydrogen and ethanol).
- the P group is silyl the chloro group can first be reduced by hydrogenation and then the protecting group can be removed using fluoride ion. Alternatively, the silyl protecting group can be removed first and then the chloro group can be reduced.
- the P group is trityl or substituted trityl
- deprotection of the P group can be effected using aqueous acid (e.g., aqueous acetic acid) and the chloro group can then be reduced.
- this compound of formula 1 can be prepared by reacting an optionally protected compound of formula with a compound of formula 5 according to the procedures analogous to those used in the preparation of a compound of formula 7, followed by removal of the protecting group(s) by methods known in the art.
- the optionally protected forms of compound 9A can be protected at the amino (-NH 2 ) group by such exemplary groups as acyl (e.g., acetyl or benzoyl), trityl, or substituted trityl.
- a compound of formula 1 wherein R 1 is and R 2 and R 3 are hydrogen can be prepared from a compound of formula 7 or from a compound of formula wherein R 1 is and R 2 and R 3 are hydrogen by methods known in the art. See, for example, J.F. Gerster, et al., J. Amer. Chem. Soc., 87, 3 75 2 ( 1 965); K.K. Ogilvie, et al., Can. J. Chem., 62, 2702 (1984); M. R. Harnden, et al., J. Med. Chem., 30, 1636 (1987).
- this compound of formula 1 can be prepared by reacting a compound of formula with a compound of formula 5 according to the procedures analogous to those used in the preparation of a compound of formula 7, followed by removal of the protecting group P by methods known in the art.
- Compounds of formula 9B can be prepared from the compound of formula 6 by methods known in the art (see, e.g., W. A. Bowles et.al., J. Med. Chem.,6, 471 (1963)).
- a compound of formula 1 wherein Ri is and R 2 and R 3 are hydrogen can be prepared from a compound of formula 7 by methods known in the art. (See e.g., J. C. Martin , et. al., J. Med. Chem., 28, 358 (1985)).
- P is a protecting group such as benzyl, silyl, trityl or substituted trityl
- displacement of the chloro group with an amino group will result.
- the protecting group P is a benzyl group
- subsequent deprotection can be accomplished by hydrogeneolysis, by sodium in liquid ammonia, or by using boron trichloride.
- the protecting group P is a silyl group
- subsequent deprotection can be accomplished using fluoride ion.
- the protecting group is a trityl or substituted trityl group
- subsequent deprotection can be accomplished using an aqueous acid.
- this compound of formula 1 can be prepared by reacting an optionally protected compound of formula with a compound of formula 5 according to the procedures analogous to those used in the preparation of a compound of formula 7, followed by removal of the protecting group(s) by methods known in the art.
- the optionally protected forms of compound 10 can be protected at the amino (-NH 2 ) groups by such exemplary groups as acyl (e.g. acetyl or benzoyl), trityl, or substituted trityl.
- the amino protecting groups are acyl
- removal of the acyl groups can be accomplished first using catalytic sodium methoxide in methanol or methanolic ammonia, and then the P protecting group can be removed, for example, by hydrogenolysis when P is benzyl, by treatment with fluoride ion when P is silyl, or by aqueous acid when P is trityl or substituted trityl.
- the silyl, benzyl or trityl protecting group P could be removed first followed by removal of the acyl protecting groups.
- simultaneous deprotection of all of the trityl groups can be accomplished using aqueous acid.
- the amino protecting groups are trityl and P is benzyl
- the trityl groups can be removed first with aqueous acid and the benzyl group can then be removed by hydrogenolysis, sodium in liquid ammonia, or boron trichloride.
- a base such as potassium carbonate, sodium hydride, or potassium hydride
- a polar aprotic solvent e.g., dimethylformamide, dimethyl sulfoxide or sulfolane
- the optionally protected forms of compounds 12, 13 and 14 can be protected at the amino (-NH 2 ) group by such exemplary groups as acyl (e.g. acetyl or benzoyl), trityl, or substituted trityl. These protecting groups can be removed by methods known in the art.
- these compounds of formula 1 can be prepared by reaction of 5 with a compound of the formula or respectively, by procedures analogous to those used in the preparation of 7 , followed by acid hydrolysis of the chloro group and simultaneous or subsequent removal of the protecting group P.
- this compound of formula 1 can be prepared by reaction of a compound of formula 5 with a compound of formula by methodology analogous to that used to prepare a compound of formula 7 and subsequent removal of the protecting group P. If the protecting group P is a benzyl group, this group can be removed by hydrogenolysis (e.g., palladium hydroxide on carbon, cyclohexene, ethanol) or by using sodium in liquid ammonia.
- hydrogenolysis e.g., palladium hydroxide on carbon, cyclohexene, ethanol
- this compound of formula 1 can be prepared by treatment of the compound of formula 1 wherein R, is and R 2 and R 3 are hydrogen with adenosine deaminase or nitrous acid.
- the protected forms of compounds 22, 23 and 24 can be protected at the amino (-NH 2 ) group by such exemplary groups as acyl (e.g. acetyl or benzoyl), trityl, or substituted trityl.
- acyl e.g. acetyl or benzoyl
- trityl e.g. trityl
- substituted trityl e.g. trityl
- the protecting groups can then be removed by methods known in the art.
- these compounds of formula 1 can be prepared by reaction of a compound of formula or with a compound of formula 5 by methods analogous to those used in the preparation of a compound of formula 7. This affords the corresponding compounds of formula wherein R 4 is or Treatment of a compound of formula 28 with hot ammonia in an alcohol and subsequent deprotection of the P protecting group yields the compound of formula 1 wherein R 1 is or and R 2 and R 3 are hydrogen.
- the compound of formula 1 wherein R 1 is and R 2 and R 3 are hydrogen can be prepared by reaction of a compound of formula with a compound of formula 5, according to the procedures analogous to those used in the preparation of compound 7, which affords an intermediate compound of formula Subsequent treatment of the compound of formula 31 with hydrazine, followed by Raney nickel reduction, using methods known in the art (e.g., R. I. Glazer, et al., Biochem. Pharmacol., 35, 4523 (1986); R. J. Rousseau, et al., Biochemistry, 5, 756 (1966)) yields a compound of formula The protecting group P in 32 can then be removed by methods known in the art.
- the protecting group P in 31 can be removed first and the corresponding deprotected compound can then be treated with hydrazine followed by Ranay nickel reduction.
- P is benzyl
- deprotection of 31 can be achieved with boron trichloride.
- P is silyl, trityl, or substituted trityl deprotection can be achieved by methods known in the art.
- the compound of formula 1 wherein R 1 is and R 2 and R 3 are hydrogen can be prepared from a compound of formula 1 wherein R 1 is and R 2 and R 3 are hydrogen by methodology known in the art (e.g, the conversion of adenosine to 2- azaadenosine; J. A. Montgomery et al. in "Nucleic Acid Chemistry” Part 2, L.B. Townsend and R. S. Tipson, Eds., John Wiley and Sons, p. 681, 1978).
- treatment of the compound of formula 34 with t-butylhydroperoxide in aqueous sulfuric acid in the presence of ferrous sulfate provides the compound of formula 33 wherein X 2 is methyl.
- treatment of the compound of formula 34 with iodine monochloride in aqueous methanol provides a compound of formula 33 wherein X 2 is iodo.
- Treatment of the compound of formula 34 with bromine water provides the compound of formula 33 wherein X 2 is bromo.
- Treatment of the compound of formula 33 wherein X 2 is bromo with refluxing aqueous hydrazine provides the compound of formula 33 wherein X 2 is amino.
- Treatment of the compound of formula 33 wherein X 2 is bromo with sodium acetate/acetic acid provides the compound of formula 33 wherein X 2 is hydroxyl.
- a compound of formula 33 wherein X 2 is fluoro can be prepared from the compound of formula 33 wherein X 2 is bromo or iodo and where the amino (-NH 2 ) and/or hydroxyl groups are optionally protected with acyl (e.g. acetyl or benzoyl) groups.
- acyl e.g. acetyl or benzoyl
- fluoride ion e.g., sodium or potassium fluoride in a solvent such as dimethylformamide or tetrabutylammonium fluoride in tetrahydrofuran
- removal of the optional acyl protecting groups using, for example, catalytic sodium methoxide in methanol or methanolic ammonia provides the compound of formula 33 wherein X 2 is fluoro.
- amino (-NH 2 ) and/or hydroxyl groups in the compound of formula 1 wherein X 5 , R 2 and R 3 are hydrogen can be optionally protected by acyl (e.g. acetyl or benzoyl) groups prior to replacement of the X s hydrogen by a methyl group. Subsequent deprotection can be accomplished by treatment with sodium methoxide in methanol or methanolic ammonia.
- acyl e.g. acetyl or benzoyl
- the compound of formula 1 wherein R 1 is and X s is fluoro and R 2 and Ra are hydrogen can be prepared from the corresponding compound of formula 1 wherein Xs is bromo or iodo and R 2 and R 3 are hydrogen.
- the amino (-NH 2 ) and/or hydroxyl groups can be optionally protected with acyl (e.g. acetyl or benzoyl) groups.
- fluoride ion e.g., sodium or potassium fluoride in a solvent such as dimethylformamide or tetrabutylammonium fluoride in tetrahydrofuran
- acyl protecting groups using, for example, catalytic sodium methoxide in methanol or methanolic ammonia
- a compound of formula 1 wherein R 1 is and R 2 and R 3 are hydrogen can be prepared from a compound of formula wherein P 1 is an acyl protecting group, (for example, acetyl or benzoyl) by methodology known in the art (e.g., M. Ikehara, et al., Chem. Commun., 1509 (1968)).
- the compound of formula 35 can be prepared by known methods from the compound of formula 1 wherein R, is and R 2 and R 3 are hydrogen by treatment with sodium azide followed by acylation of the hydroxyl groups. See, for example, R. A. Long, et al., J. Org. Chem., 32, 2751 (1967).
- the compound of formula T wherein R 1 is and R 2 and R 3 are hydrogen can be prepared from the corresponding compound of formula 1 wherein R 1 and R 2 and R 3 are hydrogen by following known procedures. See, for example J.A. Montgomery, et al. in "Synthetic Procedures in Nucleic Acid Chemistry", Vol. 1, W. W. Zorbach and R.S. Tipson, Eds., Interscience Publishers (John Wiley and Sons), N.Y., p. 205, 1968.
- the compound of formula wherein X s is hydrogen, fluoro, methyl, ethyl, 2-chloroethyl, or 2-fluoroethyl can be prepared by reaction of the corresponding compound of formula with a compound of formula 5 in the presence of a base such as potassium carbonate, sodium hydride, or potassium hydride, in an aprotic polar solvent (e.g., dimethylformamide, dimethylsulfoxide, or sulfolane), in the optional presence of 18-crown-6 or 15-crown-5, which yields an intermediate of formula Removal of the protecting group P provides the corresponding compound of formula 1 wherein R 1 is and R 2 and R 3 are hydrogen.
- a base such as potassium carbonate, sodium hydride, or potassium hydride
- an aprotic polar solvent e.g., dimethylformamide, dimethylsulfoxide, or sulfolane
- this protecting group can be removed by hydrogenolysis (e.g. palladium hydroxide on carbon and cyclohexene in ethanol) or by treatment with boron trichloride.
- P is silyl
- deprotection can be accomplished with fluoride ion.
- P is trityl or substituted trityl
- deprotection can be accomplished with aqueous acid.
- the compound of formula 37 wherein X 6 is 2-chloroethyl or 2-fluoroethyl can be prepared by methods known int he art [H. Griengl, et al., J. Med. Chem., 30, 1199 (1987); J. Med. Chem., 28, 1679 (1985)].
- the compound of formula 36 wherein X 6 is fluoro can also be prepared from the corresponding compound 36 wherein X 6 is hydrogen and the hydroxy groups are optionally protected with a group such as acyl (e.g. acetyl or benzoyl) by fluorination with trifluoromethyl hypofluorite using methodology known in the art.
- acyl e.g. acetyl or benzoyl
- T.S. Lin et al., J. Med. Chem., 26, 1691 (1983).
- compounds of formula 36 wherein X 6 is 2-chloroethyl or 2-fluoroethyl can be prepared from a compound of formula wherein P, P 2 , and P 3 are protecting groups wherein P 2 can be selectively removed in the presence of P and P 3 .
- Protecting groups P and P 3 may be the same of different.
- P 2 is a silyl, trityl, or substituted trityl group
- P can be a benzyl group and P 3 can be an acyl (e.g., acetyl or benzoyl) group. Selective removal of the protecting group P 2 yields a compound having the formula
- the compound of formula 39 can be prepared by reaction of compound having the formula with a compound of formula 5 by methods analogous to those used for the preparation of 38 (wherein, for example, X 6 is hydrogen, methyl, or ethyl) followed by protection with the P 3 group by methods known in the art.
- the compound of formula 40 can be prepared from the compound of formula by methods known in the art.
- the compound of formula wherein X 6 is hydrogen, fluoro, methyl, ethyl, 2-chloroethyl, or 2-fluoroethyl can be prepared from the compound of formula (wherein P 1 is a protecting group such as acyl, e.g., acetyl or benzoyl) by methods known in the art. See, for example, I. Wempner, et al. in "Synthetic Procedures in Nucleic Acid Chemistry", Vol. 1, W.W. Zorbach and R.S. Tipson, Eds., Interscience Publishers, N.Y., p. 299, 1968; T.S. Lin, et al., J. Med. Chem., 26, 1691 (1983); P.
- P 1 is a protecting group such as acyl, e.g., acetyl or benzoyl
- the compound of formula 42 can be prepared from the corresponding compound of formula 36 by methods known in the art.
- the compound of formula 41 wherein X 6 is fluoro, hydrogen, methyl, ethyl, 2-chloroethyl, or 2-fluoroethyl can be prepared by reaction of the corresponding compound of formula with a compound of formula 5 in the presence of a base such as potassium carbonate, sodium hydride, or potassium hydride in an aprotic solvent (e.g. dimehtylformamide, dimethyl sulfoxide, or sulfolane), in the optional presence of 18-crown-6 or 15-crown-5, and subsequent removal of the protecting group P.
- a base such as potassium carbonate, sodium hydride, or potassium hydride
- an aprotic solvent e.g. dimehtylformamide, dimethyl sulfoxide, or sulfolane
- the amino (-NH 2 ) group in 43 can be protected (e.g., with an acyl group such as acetyl of benzoyl). Removal of this protecting group can be accomplished using sodium methoxide in methanol or methanolic ammonia.
- the compound of formula 41 wherein X 6 is fluoro can be prepared from the corresponding compound wherein X 6 is hydrogen by fluorination with trifluoromethyl hypofluorite using methodology known in the art. Fluorination can also be performed on the compounds of formula 41 wherein X 6 is hydrogen and the hydroxyl and/or amino (-NH 2 ) groups are protected, for example, by an acyl such as acetyl or benzoyl. After fluorination, deprotection using methanolic ammonia or aqueous hydroxide affords the compound of formula 41 wherein X 6 is fluoro. See, for example, M.J. Robins, et al., J. Amer. Chem. Soc., 5277 (1971) and Chem. Commun., 18 (1972); T.S. Lin, et al., J. Med. Chem., 26, 1691 (1983).
- the compounds of formula 36 and 41 wherein X 6 is chloro, bromo, or iodo can be prepared from the corresponding compounds of formula 36 and 41 wherein Xs is hydrogen by methods known in the art. See, for example, "Basic Principals in Nucleic Acid Chemistry", Vol. 1, P.O.P. Ts'O, Ed., Academic Press, N.Y., p. 146, 1974; P.K. Chang in "Nucleic Acid Chemistry” Part 3, L. B. Townsend and R. S. Tipson, Eds., John Wiley and Sons, N.Y., p. 46. 1986.
- treatment of the compound of formula 36 wherein X 6 is hydrogen with iodine and nitric acid in aqueous dioxine affords the compounds of formula 36 wherein X 6 is iodo.
- the compounds of formula 36 and 41 wherein X 6 is trifluoromethyl can be prpeared from the corresponding compounds of formula 36 and 41 wherein X 6 is iodo and the hydroxy groups are protected, for example, by an acyl e.g., acetyl or benzoyl), by treatment with trifluoromethyl iodide and copper according to procedures known in the art. Subsequent deprotection using methanolic ammonia or sodium methoxide in methanol yields the corresponding compound of formula 36 and 41 wherein X 6 is trifluoromethyl. See, for example, Y. Kabayashi, et al., J. Chem. Soc., Perkin 1, 2755 (1980); S. Lin, et al., J. Med. Chem. 26, 1691 (1983).
- the compounds of formula 36 and 41 wherein X 6 is and X 9 is chloro, bromo, iodo, hydrogen or methyl can be prpeared from the corresponding compounds of formula 36 and 41 wherein X 6 is iodo or HgCl via organopalladium intermediates.
- the compounds of formula 36 and 41 wherein X 6 is -HgCI can be prepared from the corresponding compounds of formula 36 and 41 wherein X 6 is hydrogen by methods known in the art. See, for example, references in E. DeClercq, et al., Pharm. Ther., 26, 1 (1984); M. E. Perlman, et al., J. Med. Chem., 28, 741 (1985); P. Herdewijn, et al., J. Med. Chem., 28, 550 (1985).
- R 1 is X 1 and X 4 are and R 2 and R 3 are hydrogen or (or wherein X 1 and X 4 are amino (-NH 2 ), and one or both of R 2 and R 3 are can be prepared from the corresponding compounds of formula 1 wherein X, and X 4 are amino and R 2 and R 3 are hydrogen by methods known in the art. All of the other compounds of formula 1 wherein one or both of R 2 and R 3 are can be prepared by methods known in the art from the corresponding compound of formula 1 wherein R 2 and R 3 are hydrogen.
- the compounds of formula 1 wherein R 2 and/or R 3 are -PO 3 H 2 can be prepared from the corresponding compounds of formula 1 wherein R 2 and R 3 are hydrogen by procedures known in the art. See, for example, H. Schaller, et al., J. Amer. Chem. Soc., 85, 3821 (1963); J. Beres, et al., J. Med. Chem., 29, 494 (1986); R. Noyori, et al., Tet. Lett., 28, 2259 (1987); W. Pfleiderer, et al., Helv. Chim. Acta., 70, 1286 (1987); "Nucleic Acid Chemistry", Part 2, L. B. Townsend and R. S. Tipson, Eds., John Wiley and Sons, 1978.
- the compounds of formula 1 wherein R is can form acid addition salts with inorganic or organic acids.
- Illustrative are the hydrohalide (e.g. hydrochloride and hydrobromide), alkylsulfonate, sulfate, phosphate and carboxylate salts.
- the compounds of formula I wherein R 1 is can form basic salts with inorganic and organic bases.
- Illustrative are alkali metal salts (e.g., sodium and potassium), alkaline earth metal salts (e.g. calcium and magnesium), ammonium and substituted ammonium salts.
- R 2 and/or R 3 are -PO ⁇ H 2 can form basic salts with inorganic and organic bases.
- Illustrative are alkali metal salts (e.g., sodium and potassium), alkaline earth metal salts (e.g., calcium and magnesium), ammonium and substituted ammonium salts.
- the stereochemistry shown for the compounds of this invention is relative, not absolute. It is drawn to show that in the compounds of this invention, the base (Ri) is cis with respect to the -CH 2 -OR 2 substituent and trans with respect to the OR 3 substituent.
- the ethyl acetate extracts were combined and dried over anhydrous sodium sulfate and the ethyl acetate evaporated in vacuo yielding the crude product as a yellow oil.
- the material was purified on a 2-liter Merck silica gel column eluting with 3 liters of hexane, followed by 5% ethyl acetateihexane. The fractions containing the desired product were combined and the volatiles evaporated in vacuo yielding 28.6 g of the title compound as a pale yellow oil.
- a quantity of the cis an trans isomers (1:1) were separated by preparative HPLC using a "Water's Prep 500" with a 500 ml silica get column eluting with 2.5% ethyl acetate/hexane loading 2 g of mixture at 100 -ml/minute and then eluting the column at a flow rate of 200 ml/minute (total 10 g of mixture used). Peak shaving technique was used to enrich one isomer over the other, with the mixture being recycled through the column 3 times. A total of 2.1 g of trans epoxide and 2.48 of cis epoxide were separated.
- the trans-enriched mixture was further purified by preparative HPLC using a "Waters Prep 500" equipped with two tandem 500 ml silica gel column eluting with 5% ethyl acetate/pentane loading 4 g of the mixture at a time (at a flow rate of 250 ml/minute). A total of 20.5 g of material was loaded in this fashion. Peak shaving technique was used to enrich one isomer over the other, with the mixture being recycled back through the column once. Eventually, 6.91 g of essentially pure (1a,2a,4a)-2-[(phenylmethoxy)methyl]-5- oxabicyclo[2.1.0]pentane was isolated in this fashion. Total recovery was 10.93 g.
- the ether extract was washed with 200 ml of water, 200 ml of saturated sodium bicarbonate and 200 ml of saturated sodium chloride solution.
- the ether extract was dried over anhydrous sodium sulfate, filtered and the ether removed in vacuo yielding 1.1 grams of crude mixture.
- the crude material was purified on a 100 ml Merck silica column eluting with 500 ml of hexanes followed by eluting with 1000 ml of 21 ⁇ 2 % ethyl acetate/hexanes. All fractions containing cis and trans-epoxide were combined. The volatiles were removed in vacuo yielding 478 mg of a 1:2.5 mixture of cis and trans isomers, respectively.
- the volatiles were then removed by allowing a slow stream of nitrogen to pass through the reaction mixture yielding the crude product as a colorless solid.
- the crude solid was dissolved in 20 ml of water and the pH was adjusted from pH 12.6 to pH 7.0 by adding 1 N hydrochloric acid solution. When the pH reached 10 the product began to precipitate from solution. The precipitated product was collected by centrifugation and was washed twice with col water (2 x 4 ml). The resulting colorless solid was dried in vacuo overnight at room temperature yielding 134 mg of the title product, melting point 246° C (dec.)
- valatiles were removed at 40 C on the "Kugelrohr” apparatus yielding the crude product as a brown solid.
- the residue was partially dissolved in 8 ml of methylene chloride and purified on a 400 ml Whatman LPS-1 silica column eluting with 800 ml of methylene chloride followed by 1200 ml of 2% methanol-methylene chloride collecting 12 ml fractions.
- the fractions containing the pure desired product were combined and the volatiles removed in vacuo yielding the title product as a colorless solid, 70 mg.
- the material was dissolved in 4 ml of water containing a few drops of acetonitrile and purified on a 20 ml HP-20 column, eluting the column with 200 ml of a 50% acetonitrile-water/water gradient, collecting 6 ml fractions.
- the fractions containing pure product were combined, the acetonitrile was removed in vacuo, and the water lyophilized to yield 42 mg of the title product as a colorless solid having m.p. 186° C (dec).
- the orange oily solid residue was preadsorbed on silica gel (Baker reagent, 60-230 mesh(0.063-0.250 mm)) and purified by flash chromatography (silica gel,0.037-0.063mm (230-400 mesh), 5 cm x 33 cm), eluting with methylene chloride and then a stepwise gradient of methanolmethylene chloride (1-5%). This gave the title compound (0.37 g) as a colorless powder.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Epoxy Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
Abstract
Description
-
- R1 is
- X2 is methyl, fluoro, chloro, bromo, iodo, hydroxy, or amino,
- X3 is hydrogen, chloro, or O-X8,
- X4 is amino,
- Xs is hydrogen, methyl, fluoro, chloro, bromo, iodo, hydroxy, or amino,
- Xs is fluoro, chloro, bromo, iodo, hydrogen, methyl, trifluoromethyl, ethyl, 2-fluoroethyl, 2-chloroethyl, or
- X7 is hydrogen, alkyl, substituted alkyl, or aryl,
- X8 is alkyl,
- Xg is chloro, bromo, iodo, hydrogen, or methyl,
- R2 and R3 are independently hydrogen, -P03H2, or
- The term "alkyl" refers to both straight and branched chain groups. Those groups having 1 to 10 carbons are preferred. The term "substituted alkyl" refers to alkyl groups having one or more substituents. Preferred substituents are halogen, amino, azido, hydroxy, cyano, trialkylammonium (wherein each alkyl group has 1 to 6 carbons), alkoxy of 1 to 6 carbons, aryl and carboxy. The term "aryl" refers to phenyl and phenyl substituted with one, two or three substituents. Preferred substituents are alkyl of 1 to 6 carbons, alkoxy or 1 to 6 carbons, halogen, trifluoromethyl, amino, alkylamino, dialkylamino, nitro, cyano, alkanoyloxy of 2 to 11 carbons, carboxy, carbamoyl and hydroxy.
- The compounds of formula 1, and the pharmaceutically acceptable salts thereof, are antivital agents that can be used to treat viral infection in mammalian species such as domesticated animals (e.g., dogs, cats, horses and the like) and humans, and avian species (e.g., chickens and turkeys). The compounds of formula 1 wherein R1 is
- For internal infections, the compounds may be administered orally or parenterally in an amount effective to treat the infection. The dosage will, of course, depend on the severity of the infection, but will likely be in the range of about 1.0 to 30 mg/kg of body weight.
- For infections of the eye, or other external tissues, (e.g., mouth and skin) the compositions may be applied to the infected part of the body of the patient topically as an ointment, cream, aerosol, gel, powder, lotion, suspension or solution (e.g., as eye drops). The concentration of the compound in the vehicle will, or course, depend on the severity of the infection, but will likely be in the range of about 0.1 to 7% by weight.
- The compounds of this invention can be prepared from the known chemical compound 1-chloro-3-(hydroxymethyl)cyclobutane, which is a racemic mixture of cis and trans diasteriomers. Its hydroxymethyl group is first protected using, for example, a silyl containing group (e.g., a hindered trisubstituted silyl such as t-butyldiphenylsilyl, di-t-butylmethylsilyl, or triisopropylsilyl), trityl, substituted trityl (e.g., 4-monomethoxytrityl or 4,4 -dimethoxytrityi), or benzyl protecting group. The protection reaction yields a compound of the formula
- Protection with a benzyl group can be accomplished by treating 1-chloro-3-(hydroxymethyl) cyclobutane with sodium hydride in the presence of benzyl bromide in a polar aprotic solvent such as dimethylformamide, dimethylsulfoxide or tetrahydrofuran. Protection with a t-butyldiphenylsilyl group can be accomplished by treating a dimethylformamide solution of 1-chloro-3-(hydroxymethyl)cyclobutane with t-butyldiphenylsilyl chloride in the presence of imidazole. Protection with a trityl or substituted trityl group can be accomplished by (i) treating a pyridine solution of 1-chloro-3-(hydroxymethyl)cyclobutane with trityl chloride or substituted trityl chloride, (ii) treating a dimethylformamide solution of 1-chloro-3-(hydroxy methyl)cyclobutane with trityl chloride or substituted trityl chloride in the presence 4-N,N-dimethylaminopyridine or (iii) treating a dichloromethane solution of 1-chloro-3-(hydroxymethyl)cyclobutane with trityl chloride or substituted trityl chloride in the presence of triethylamine.
- Basic elimination of hydrogen chloride from a compound of formula 2 using a base such as potassium t-butoxide in a polar aprotic solvent, such as dimethylsulfoxide or tetrahydrofuran yields the corresponding compound having the formula
- Epoxidation of a compound of formula 3 using a peracid, such as m-chloroperoxybenzoic acid yields the corresponding compound having the formula
- Nucleophilic substitution on the epoxide of a compound of formula 5 using a compound of formula
- Optionally, the reaction can be run in the presence of a metal chelating catalyst such as 18-crown-6 (1,4,7,10,13,16-hexaoxacyclooctadecane) or 15-crown-5 (1,4,7,10,13-pentaoxacyclopentadecane).
- Removal of the protecting group P from a compound of formula 7 yields a compound of formula 1 wherein R1 is
-
-
- When the protecting group P in 9 is benzyl, simultaneous removal of the P group and the purine 0-benzyl group can be effected by using sodium in liquid ammonia, by hydrogenolysis (e.g., palladium hydroxide on carbon, cyclohexene, and ethanol), or by using boron trichloride in dichloromethane. Alternatively, the purine O-benzyl group can be removed first using aqueous alcoholic mineral acid followed by removal of the P group using, for example, sodium in liquid ammonia or hydrogenolysis. When the protecting group P is a silyl protecting group, removal of the P group can be accomplished using fluoride ion (e.g., tetrabutylammonium fluoride in tetrahydrofuran). The purine O-benzyl group can then be removed with aqueous alcoholic mineral acid, by hydrogeneolysis, or with sodium in liquid ammonia. Alternatively, the purine O-benzyl group can be deprotected first by hydrogenolysis followed by removal of the silyl P group using fluoride ion. When the protecting group P is a trityl or substituted trityl group, removal of the P group and the purine O-benzyl group can be accomplished simultaneously using aqueous/alcoholic mineral acid.
- Alternatively this compound of formula 1 can be prepared from a compound of formula 7. For example, when the protecting group P in 7 is benzyl, removal of the P group can be effected first by treatment with boron trichloride, and then the chloro group can be hydrolized using aqueous acid (e.g., aqueous hydrochloric acid). Alternatively, the chloro group can be hydrolized first followed by removal of the benzyl group. When the protecting group P in 7 is silyl, the protecting group can be removed by treatment with fluoride ion, and then the chloro group can be hydrolized. When the protecting group P in 7 is a trityl or substituted trityl group, the protecting group can be removed and the chloro group can be simultaneously hydrolized using aqueous acid.
- Alternatively this compound of formula 1 can be prepared by removal of the protecting group P from a compound of formula 7 followed by treatment with adenosine deaminase by methods known in the art (e.g., M. J. Robins and P. W Hatfield, Can. J. Chem., 60, 547 (1982)).
- A compound of formula 1 wherein Ri is
- Alternatively, this compound of formula 1 can be prepared by reacting an optionally protected compound of formula
- A compound of formula 1 wherein R1 is
- Alternatively, this compound of formula 1 can be prepared by reacting a compound of formula
- A compound of formula 1 wherein Ri is
- Alternatively, this compound of formula 1 can be prepared by reacting an optionally protected compound of formula
- Reaction of a compound of formula 5 with an optionally protected compound of formula
- The optionally protected forms of compounds 12, 13 and 14 can be protected at the amino (-NH2) group by such exemplary groups as acyl (e.g. acetyl or benzoyl), trityl, or substituted trityl. These protecting groups can be removed by methods known in the art.
- Alternatively, these compounds of formula 1 can be prepared by reaction of 5 with a compound of the formula
- Reaction of a compound of formula 5 with a compound of formula
- A!ternatively, this compound of formula 1 can be prepared by reaction of a compound of formula 5 with a compound of formula
-
-
- Reaction of the compound of formula 5 with a compound of formula
- The protected forms of compounds 22, 23 and 24 can be protected at the amino (-NH2) group by such exemplary groups as acyl (e.g. acetyl or benzoyl), trityl, or substituted trityl. The protecting groups can then be removed by methods known in the art.
- Alternatively, these compounds of formula 1 can be prepared by reaction of a compound of formula
- Reaction of a compound having the formula 5 with an optionally protected compound having the formula
- The compound of formula 1 wherein R1 is
- The compound of formula 1 wherein R1 is
-
- For example, treatment of the compound of formula 34 with t-butylhydroperoxide in aqueous sulfuric acid in the presence of ferrous sulfate provides the compound of formula 33 wherein X2 is methyl. Treatment of the compound of formula 34 with dry hydrogen chloride and m =-chloroperoxybenzoic acid in dimethylformamide provides the compound of formula 33 wherein X2 is chloro. Treatment of the compound of formula 34 with iodine monochloride in aqueous methanol provides a compound of formula 33 wherein X2 is iodo. Treatment of the compound of formula 34 with bromine water provides the compound of formula 33 wherein X2 is bromo. Treatment of the compound of formula 33 wherein X2 is bromo with refluxing aqueous hydrazine provides the compound of formula 33 wherein X2 is amino. Treatment of the compound of formula 33 wherein X2 is bromo with sodium acetate/acetic acid provides the compound of formula 33 wherein X2 is hydroxyl.
- A compound of formula 33 wherein X2 is fluoro can be prepared from the compound of formula 33 wherein X2 is bromo or iodo and where the amino (-NH2) and/or hydroxyl groups are optionally protected with acyl (e.g. acetyl or benzoyl) groups. Treatment with fluoride ion (e.g., sodium or potassium fluoride in a solvent such as dimethylformamide or tetrabutylammonium fluoride in tetrahydrofuran) followed by removal of the optional acyl protecting groups using, for example, catalytic sodium methoxide in methanol or methanolic ammonia provides the compound of formula 33 wherein X2 is fluoro.
- Compounds of formula 1 wherein R, is
- The compound of formula 1 wherein R1 is
- Compounds of formula 1 wherein R1 is
- A compound of formula 1 wherein R1 is
- The compound of formula T wherein R1 is
- The compound of formula
- For example, when P is benzyl, this protecting group can be removed by hydrogenolysis (e.g. palladium hydroxide on carbon and cyclohexene in ethanol) or by treatment with boron trichloride. When P is silyl, deprotection can be accomplished with fluoride ion. When P is trityl or substituted trityl, deprotection can be accomplished with aqueous acid.
- The compound of formula 37 wherein X6 is 2-chloroethyl or 2-fluoroethyl can be prepared by methods known int he art [H. Griengl, et al., J. Med. Chem., 30, 1199 (1987); J. Med. Chem., 28, 1679 (1985)].
- The compound of formula 36 wherein X6 is fluoro can also be prepared from the corresponding compound 36 wherein X6 is hydrogen and the hydroxy groups are optionally protected with a group such as acyl (e.g. acetyl or benzoyl) by fluorination with trifluoromethyl hypofluorite using methodology known in the art. For example, see M.J. Robins, et al., J. Amer. Chem. Soc., 93, 5277 (1971) and Chem. Commun., 18,1972; T.S. Lin, et al., J. Med. Chem., 26, 1691 (1983).
- Alternatively, compounds of formula 36 wherein X6 is 2-chloroethyl or 2-fluoroethyl can be prepared from a compound of formula
- Treatment of compound of formula 39a with triphenylphospine-carbon tetrachloride or diethylaminosul- fur trifluoride, and subsequent removal of protecting groups P and P3, affords the compound having the formula 36 wherein X6 is 2-chloroethyl or 2-fluoroethyl, respectively.
- Treatment of a compound 39a with triphenylphosphine/N-bromosuccinomide or triphenylphosphine/N- bromosuccinimide/tetrabutylammonium iodide (see H. Griengl, et al., J. Med. Chem., 28, 1679 (1985)) affords compounds having the formula
- The compound of formula 39 can be prepared by reaction of compound having the formula
- The compound of formula
- Alternatively, the compound of formula 41 wherein X6 is fluoro, hydrogen, methyl, ethyl, 2-chloroethyl, or 2-fluoroethyl, can be prepared by reaction of the corresponding compound of formula
- Alternatively, the compound of formula 41 wherein X6 is fluoro can be prepared from the corresponding compound wherein X6 is hydrogen by fluorination with trifluoromethyl hypofluorite using methodology known in the art. Fluorination can also be performed on the compounds of formula 41 wherein X6 is hydrogen and the hydroxyl and/or amino (-NH2) groups are protected, for example, by an acyl such as acetyl or benzoyl. After fluorination, deprotection using methanolic ammonia or aqueous hydroxide affords the compound of formula 41 wherein X6 is fluoro. See, for example, M.J. Robins, et al., J. Amer. Chem. Soc., 5277 (1971) and Chem. Commun., 18 (1972); T.S. Lin, et al., J. Med. Chem., 26, 1691 (1983).
- The compounds of formula 36 and 41 wherein X6 is chloro, bromo, or iodo can be prepared from the corresponding compounds of formula 36 and 41 wherein Xs is hydrogen by methods known in the art. See, for example, "Basic Principals in Nucleic Acid Chemistry", Vol. 1, P.O.P. Ts'O, Ed., Academic Press, N.Y., p. 146, 1974; P.K. Chang in "Nucleic Acid Chemistry" Part 3, L. B. Townsend and R. S. Tipson, Eds., John Wiley and Sons, N.Y., p. 46. 1986. For example, treatment of the compound of formula 36 wherein X6 is hydrogen with iodine and nitric acid in aqueous dioxine affords the compounds of formula 36 wherein X6 is iodo.
- The compounds of formula 36 and 41 wherein X6 is trifluoromethyl can be prpeared from the corresponding compounds of formula 36 and 41 wherein X6 is iodo and the hydroxy groups are protected, for example, by an acyl e.g., acetyl or benzoyl), by treatment with trifluoromethyl iodide and copper according to procedures known in the art. Subsequent deprotection using methanolic ammonia or sodium methoxide in methanol yields the corresponding compound of formula 36 and 41 wherein X6 is trifluoromethyl. See, for example, Y. Kabayashi, et al., J. Chem. Soc., Perkin 1, 2755 (1980); S. Lin, et al., J. Med. Chem. 26, 1691 (1983).
- The compounds of formula 36 and 41 wherein X6 is
- Compounds of the formula 1 wherein R1 is
- For examples of acylation procedures, see "Synthetic Procedures in Nucleic Acid Chemistry", Vol. 1, W. W. Zorbach and R. S. Tipson, Eds., John Wiley and Sons, 1968; "Nucleic Acid Chemistry," Part 1, L. B. Townsend and R. S. Tipson, Eds., John Wiley and Sons, 1978; Y. Ishido, et al., Nuclesides and Nucletides, 5, 159 (1986); J. C. Martin, et al., J. Pharm. Sci., 76, 180 (1987); A. Matsuda, et al., Synthesis, 385 (1986).
- Compounds of the formula wherein R1 is
- The compounds of formula 1 wherein R2 and/or R3 are -PO3H2 can be prepared from the corresponding compounds of formula 1 wherein R2 and R3 are hydrogen by procedures known in the art. See, for example, H. Schaller, et al., J. Amer. Chem. Soc., 85, 3821 (1963); J. Beres, et al., J. Med. Chem., 29, 494 (1986); R. Noyori, et al., Tet. Lett., 28, 2259 (1987); W. Pfleiderer, et al., Helv. Chim. Acta., 70, 1286 (1987); "Nucleic Acid Chemistry", Part 2, L. B. Townsend and R. S. Tipson, Eds., John Wiley and Sons, 1978.
-
-
- The compounds of formula I wherein R2 and/or R3 are -POε H2 can form basic salts with inorganic and organic bases. Illustrative are alkali metal salts (e.g., sodium and potassium), alkaline earth metal salts (e.g., calcium and magnesium), ammonium and substituted ammonium salts.
- The stereochemistry shown for the compounds of this invention is relative, not absolute. It is drawn to show that in the compounds of this invention, the base (Ri) is cis with respect to the -CH2-OR2 substituent and trans with respect to the OR3 substituent.
- The following examples are specific embodiments of this invention.
- A mixture of 3-chlorocyclobutanemethanol (17.3 g, 0.143 mole) and benzylbromide (26.96 g, 0.158 mole) in dry dimethylformamide (123 ml) was stirred at room temperature under an argon atmosphere and a 60% suspension of sodium hydride (6.31 g 0.158 g mole) was added. The reaction was stirred at ambient temperature for 22.5 hours. The reaction mixture was poured into 600 ml of water and the aqueous mixture extracted with ethyl acetate (4 x 500 ml). The ethyl acetate extracts were combined and dried over anhydrous sodium sulfate and the ethyl acetate evaporated in vacuo yielding the crude product as a yellow oil. The material was purified on a 2-liter Merck silica gel column eluting with 3 liters of hexane, followed by 5% ethyl acetateihexane. The fractions containing the desired product were combined and the volatiles evaporated in vacuo yielding 28.6 g of the title compound as a pale yellow oil.
- [[(3-Chlorocyclobutyl)methoxy]methyl]benzene 82 g, 0.39 mole) in 390 ml of dry dimethylsulfoxide was slowly added to a solution of potassium t-butoxide (132 g, 1.17 mole) in 390 ml of dry dimethylsulfoxide in a water-bath at 18°C under a dry argon atmosphere. After stirring for 1 hour at room temperature, the reaction mixture was poured into 1600 ml of water and extracted with ether (3 x 1000 ml). The combined ether extracts were back-extracted with water (4 x 2000 ml), the extracts were then dried over sodium sulfate, and the volatiles were removed in vacuo. The crude product was divided into two equal portions and each portion was purified on separate 3.5 liter Merck silica columns, eluting with 3% ethyl acetatehexane. Appropriate fractions were combined and the solvents removed in vacuo yielding 60.0 g of the title compound as a colorless liquid.
- A solution of 80% m-chloroperoxybenzoic acid (19.0 g, 0.088 mol) in 600 ml of dichloromethane was cooled to 0 C and a solution of [(2-cyclobuten-1-ylmethoxy)methyl]benzene (14.0 g, 0.080 mol) in 50 ml of dichloromethane was added and the resulting mixture was stirred overnight at 5 C under an argon atomosphere. The precipitated m-chlorobenzoic acid was removed by filtration, and the dichloromethane solution was washed with 5% sodium thiosulfate (1 x 500 ml), saturated sodium bicarbonate (3 x 500 ml), and water (2 x 500 ml). The dichloromethane solution was then dried over anhydrous sodium sulfate. The solution was filtered and the dichloromethane was evaporated in vacuo yielding 11.6 g of 1:1 mixture of cis and trans product.
- A quantity of the cis an trans isomers (1:1) were separated by preparative HPLC using a "Water's Prep 500" with a 500 ml silica get column eluting with 2.5% ethyl acetate/hexane loading 2 g of mixture at 100 -ml/minute and then eluting the column at a flow rate of 200 ml/minute (total 10 g of mixture used). Peak shaving technique was used to enrich one isomer over the other, with the mixture being recycled through the column 3 times. A total of 2.1 g of trans epoxide and 2.48 of cis epoxide were separated.
- A crude mixture of cis and trans epoxide (1:1, 58 g) was isolated from two separate m-chloroperoxybenzoic acid oxidations of two 27.05 g batches of [(2-cyclobuten-1-ylmethoxy)methyl] benzene following the general procedure described above. Two equal 29 g portions were purified on two separate 3.5 liter silica gel columns eluting with 5% ethyl acetate/pentane. The fractions containing essentially pure (1α,2α,4α)-2-[-(phenylmethoxy)methyl]-5-oxabicyclo(2.1.0]pentane were combined and the solvents removed in vacuo yielding 4.02 g of desired compound. Those fractions containing a greater than 1:1 ratio of trans epoxide were combined and the solvents removed in vacuo yielding 20.5 g of a mixture enriched in trans epoxide.
- The trans-enriched mixture was further purified by preparative HPLC using a "Waters Prep 500" equipped with two tandem 500 ml silica gel column eluting with 5% ethyl acetate/pentane loading 4 g of the mixture at a time (at a flow rate of 250 ml/minute). A total of 20.5 g of material was loaded in this fashion. Peak shaving technique was used to enrich one isomer over the other, with the mixture being recycled back through the column once. Eventually, 6.91 g of essentially pure (1a,2a,4a)-2-[(phenylmethoxy)methyl]-5- oxabicyclo[2.1.0]pentane was isolated in this fashion. Total recovery was 10.93 g.
- To a mixture of benzonitrile (0.80 ml, 7.8 mmol) and potassium bicarbonate (170 mg, 1.7 mmol) in 12 ml of methanol was added [(2-cyclobuten-1-ylmethoxy)methyl]benzene (523 mg, 3.0 mmol) in 12 ml of chloroform followed by the addition of 1 ml of 30% hydrogen peroxide. The mixture was rapidly stirred at room temperature under an argon atmosphere for 92 hours. The reaction was poured into 75 ml of 5% sodium thiosulfate and was extracted with 200 ml of ether. The ether extract was washed with 200 ml of water, 200 ml of saturated sodium bicarbonate and 200 ml of saturated sodium chloride solution. The ether extract was dried over anhydrous sodium sulfate, filtered and the ether removed in vacuo yielding 1.1 grams of crude mixture. The crude material was purified on a 100 ml Merck silica column eluting with 500 ml of hexanes followed by eluting with 1000 ml of 2½ % ethyl acetate/hexanes. All fractions containing cis and trans-epoxide were combined. The volatiles were removed in vacuo yielding 478 mg of a 1:2.5 mixture of cis and trans isomers, respectively.
- Freshly dried (65° C @ 0.1 mm Hg overnight) 2-amino-6-benzyloxypurine (1.21 g, 5.0 mmol) and (1α,2α,4α)-2-[(phenylmethoxy)methyl]-5-oxabicyclo[2.1.0]-pentane (571 mg, 3.0 mmol) were dissolved in 13 ml of dry dimethylformamide under an argon atmosphere. 60% Sodium hydride (60 mg, 1.5 mmol) was added to the reaction mixture at room temperature and the reaction was then heated at 110 °C for 3 days. The reaction was cooled to room temperature and the dimethylformamide was evaporated under vacuum at 40° C yielding the crude product as a brown solid. The residue was partially dissolved in 8 ml of dichloromethane and purified on a 500 ml Whatman LPS1 silica column eluting with 1500 ml of dichloromethane followed by 300 ml of 2% methanol/dichloromethane collecting 20 ml fractions. The fractions containing pure product were combined and the volatiles removed in vacuo yielding the title compound as a colorless solid, 336 mg.
- To a stirring suspension of (1α,2α,4α)-2-[(phenyl-methoxy)methyl]-5-oxabicyclo[2.1.0]pentane (57.1 mg, 0.30 mmol), 2-amino-6-benzyloxypurine (121.0 mg, 0.50 mmol, dried for 24 hours at 80 C, 1 mm Hg, over P2O5), and 18-crown-6 ether (61.0 mg, 0.23 mmol) in sulfolane (1.3 ml, dried over 3 A molecular sieves) at room temperature under argon was added sodium hydride (7.0 mg, 0.175 mmol, 60% oil dispension). After the mixture was heated to 110° C, the solution became homogeneous. After 21 hours at 110 C, the reaction was cooled to room temperature and was quenched with acetic acid (0.025 ml).
- Most of the solvent was removed by distillation (0.3 mm Hg) leaving an orange oily residue. This residue was purified by silica gel chromatography (Merck; 230-400 mesh (0.037-0.063 mm)),eluting with CH2Cl2, 1%, 2%, and then 3% MeOH:CH2CI2 to give the pure coupled product (54.8 mg).
- (1 α,2β3,4β)-2-[2-Amino-6-(phenylmethoxy)-9H-purin-9-yl]-4-[(phenylmethoxy)methyl]cyclobutanol (336 mg, 0.78 mmol) in 3 ml of dry, distilled tetrahydrofuran was added to 30 ml of liquid ammonia at -78 C under an argon atmosphere. With stirring, finely cut sodium (165 mg, 7.2 mmol) was added and when the mixture became dark blue in color the cooling bath was removed and the mixture was allowed to stir for 10 minutes. The reaction was quenched by adding small portions of ammonium chloride until the reaction became colorless. The volatiles were then removed by allowing a slow stream of nitrogen to pass through the reaction mixture yielding the crude product as a colorless solid. The crude solid was dissolved in 20 ml of water and the pH was adjusted from pH 12.6 to pH 7.0 by adding 1 N hydrochloric acid solution. When the pH reached 10 the product began to precipitate from solution. The precipitated product was collected by centrifugation and was washed twice with col water (2 x 4 ml). The resulting colorless solid was dried in vacuo overnight at room temperature yielding 134 mg of the title product, melting point 246° C (dec.)
-
- A mixture of dried adenine (557 mg, 4.125 mmol) and (1α,2α,4α)-2-[(phenylmethoxy)methyl]-5- oxabicyclo[2.1.0]pentane (523 mg, 2.75 mmol; see example 1C) was partially dissolved-in 5.5 ml of dry dimethylformamide under an argon atmosphere. To this mixture was added potassium carbonate (95 mg, 0.69 mmol) followed by 18-crown-6 ether (330 mg, 1.25 mmol) and then the mixture was heated at 110° C for 50 hours. The reaction was cooled to room temperature, and the volatiles were removed under vacuum at 40 C yielding the crude product as a brown solid. The residue was partially dissolved in 10 ml of dichloromethane and purified on a 250 ml Whatman LPS1 silical gel column, eluting with 750 ml of dichloromethane followed by 2000 ml of 28 % methanol/dichloromethane. The fractions containing the pure desired product were combined and the volatiles removed in vacuo yielding the title compound as a colorless solid, 212 mg.
- (1α,2β,4β)-2-(6-Amino-9H-purin-yl)-4-[(phenylmethoxy)methyl]cyclobutanol (200 mg, 0.615 mmol) was dissolved in 40 ml of absolute ethanol and 20 ml of cyclohexene. 20% Palladium hydroxide (140 mg) was added and the mixture was heated at reflux for 24 hours. At this point, an additional 70 mg of 20% palladium hydroxide catalyst was added, and after another 8 and10 hours two 70 mg portions of catalyst were again added. After refluxing for a total of 66 hours, the reaction was filtered through a "Millipore" filter to remove the catalyst and the catalyst was washed with approximately 10 ml of ethanol. The volatiles were removed in vacuo yielding the crude product as a colorless solid. The material was dissolved in 5 ml of water and purified on a 50 ml HP-20 column eluting with 600 ml of a 50% acetonitrile-water/water gradient. The fractions containing pure product were combined, the acetonitrile removed in vacuo, and the water lyophilized to yield 59 mg of product as a colorless solid, melting point 240° (dec.)
- Nitrogen was bubbled through a solution of (1α,2β,3α)-9-[2-hydroxy-3-(hydroxymethyl)cyclobutyl]-guanine (74 mg; 0.3 mmol) and FeSO4.·7H2O (278 mg; 1 mmol) in 16 ml of 1 M H2SO4 to remove traces of oxygen. After 30 minutes the reaction was blanketed with argon and tertiary butyl hydroperoxide (500 mg, 70% solution in water; 4 mmol) in 3 ml of water was added dropwise over 30 minutes. After stirring for 2 hours, the reaction mixture was neutralized with 1 N NaOH and the resulting dark brown suspension was centrifuged to remove the viscous brown sludge. The clear colorless supernate was loaded onto an HP-20 column (2.5 x 15 cm) which was eluted with 1 liter of water followed by a linear gradient from water to 25% acetonitrile-water. The pure desired fractions were concentrated and lyophilized to afford 37 mg of the title product as a white solid having m.p. 228 - 232 C (dec.).
- (1α,2β,3β)-9-[2-Hydroxy-3-(hydroxymethyl)cyclobutyl]guanine (225 mg; 0.9 mmol) was suspended in water (35 ml) at room temperature. Bromine water (which was prepared by stirring 2 ml of bromine in 75 ml of water and decanting off the supernatant after 10 minutes) (7 ml) was added dropwise over 5 minutes. After this addition, the suspension became a solution for five minutes, and then a precipitate reappeared. TLC (Silica gel, 6:3:1, chloroform: methanol: conc. ammonia) of an aliquot of the suspension dissolved in dimethylformamide showed only partial reaction. only partial reaction. An additional 2 ml of bromine water was added and the TLC showed that a trace of starting material remained. Then 0.5 ml of bromine water was added. After a total reaction time of approximately 1 hour, the reaction mixture was cooled to 0 C. The solid was filtered, washed with cold water, and dried to afford 292 mg, of crude title product. A 120 mg portion was recrystallized from hot water to afford 112 mg, of the title product as an off white solid having m.p. >240* C.
- (1 α,2β,3α)-2-Amino-8-bromo-1,9-dihydro-9-[2-hydroxy-3-(hydroxymethyl))cyclobutyl]-6H-purine-6-one (155 mg; 0.47 mmol) was refluxed in 7 ml of water and 0.36 ml of hydrazine-hydrate for 168 hours (7 days). After each 24 hour period, 0.2 ml of hydrazine-hydrate and 0.5 ml of water were added to the refluxing suspension. The solvents were removed in vacuo and the white solid residue was triturated with water to remove inorganics. The residue was loaded onto an HP-20 column (2.5 x 45 cm) which was eluted with a continuous gradient from water to water-dimethylformamide, 1:1. The pure product containing fractions were concentrated to a white powder. This powder was suspended in water and filtered to remove residual dimethylformamide. Drying in vacuo for 18 hours over CaSO4. afforded 50 mg of the title product as a white powder having m.p. 225 C (dec.).
- A mixture of dried thymine (380 mg, 3.0 mmol) and 1α,2α,4α-[(phenylmethoxy)methyl]-5-oxabicyclo-[2.1.0]pentane (380 mg, 2.0 mmol) were dissolved in 4 ml of dimethylformamide under an argon atmosphere. To this mixture was added potassium carbonate (35 mg, 0.25 mmol) followed by 18-crown-6 (120 mg, 0.45 mmol) and then the mixture was heated at 110°C for 68 hours. The reaction progress was monitored by TLC. The reaction was cooled to room temperature, a few drops of acetic acid was added and the mixture stirred for 20 minutes. The valatiles were removed at 40 C on the "Kugelrohr" apparatus yielding the crude product as a brown solid. The residue was partially dissolved in 8 ml of methylene chloride and purified on a 400 ml Whatman LPS-1 silica column eluting with 800 ml of methylene chloride followed by 1200 ml of 2% methanol-methylene chloride collecting 12 ml fractions. The fractions containing the pure desired product were combined and the volatiles removed in vacuo yielding the title product as a colorless solid, 70 mg.
- (1α,2β,3α)-1-[2-Hydroxy-3-(phenylmethoxy)methyl)-cyclobutyl]-5-methyl-2,4(1H,3H)-pyrimidinedione (70 mg, 0.22 mmol) was dissolved in 6 ml of 95% ethanol and 2 ml of cyclohexene. 20% Palladium hydroxide (70 mg) was added and the mixture was stirred 26 hours at room temperature. TCL showed no starting material remaining. The catalyst was removed by filtering through a "Millipore" filter and washing the catalyst with 10 ml of EtOH. The volatiles were removed in vacuo yielding the crude product as a colorless solid. The material was dissolved in 4 ml of water containing a few drops of acetonitrile and purified on a 20 ml HP-20 column, eluting the column with 200 ml of a 50% acetonitrile-water/water gradient, collecting 6 ml fractions. The fractions containing pure product were combined, the acetonitrile was removed in vacuo, and the water lyophilized to yield 42 mg of the title product as a colorless solid having m.p. 186° C (dec).
- A mixture of (1α,2α,4α)-2-[(phenylmethoxy)methyl]-5-oxabicyclo[2.1.0]pentane (380 mg; 2 mmol), cytosine (456 mg; 4.1 mmol), 18-crown-6 (400 mg, 1.5 mmol), and K2CO3 (140 mg, 1 mmol) was stirred in sulfolane (8 ml) at 120°C for 24 hours. The solvent was removed by Kugelrohr distillation under high vacuum at 85 C. The residue was loaded onto a 2.5 x 40 cm silica gel column. The column was eluted with a stepwise gradient from methylene chloride to 16% methanol-methylene chloride. The pure practions containing desired compound were concentrated to afford 280 mg of the title compound contaminated with 18-crown-6. Trituration with diethyl ether and drying afforded 240 mg* of the title compound (This material was 89% pure by 270 MHz NMR. The impurity, 18-crown-6 was 11% and accounted for 29 mg. Corrected yield: 211 mg). ,
- A mixture of (1α,2β,3α)-4-amino-1-[2-hydroxy-3-(phenylmethoxy)methyl)cyclobutyl]-2(1H)-pyrimidinone (175 mg; 0.58 mmol), 20% Pd(OH)2 on carbon (175 mg) and cyclohexene (4.3 ml) was heated at reflux in 20 ml of 95% ethanol for 6 hours. The mixture was filtered through celite and the filter cake was washed well with 95% ethanol. The filtrate was concentrated to dryness and co-evaporated with water (2 x 20 ml) to drive off residual ethanol. The residue was loaded onto a HP-20 column (2.5 x 20 cm) and was eluted with a continuous gradient from water to 30% acetonitrile-water. Pure fractions were concentrated and lyophilized to afford 87 mg of the title product as a fluffy white solid having m.p. 205° - 210 C (dec).
- A mixture of (1α,2α,4α)-2-[phenylmethoxy)methyl]-5-oxabicyclo[2.1.0]pentane (0.552 g, 2.9 mmol), uracil (1.3 g, 11.6 mmol), NaH (65 mg of a 60% suspension, 1.62 mmol), and 18-crown-6 (0.61 g, 2.3 mmol) in sulfolane (13 ml) was heated at 115 °C for 110 hours. The reaction mixture was quenched with acetic acid (0.1 ml) and the solvent was removed by Kugelrohr distillation (80 C, 0.25 mm Hg). The orange oily solid residue was preadsorbed on silica gel (Baker reagent, 60-230 mesh(0.063-0.250 mm)) and purified by flash chromatography (silica gel,0.037-0.063mm (230-400 mesh), 5 cm x 33 cm), eluting with methylene chloride and then a stepwise gradient of methanolmethylene chloride (1-5%). This gave the title compound (0.37 g) as a colorless powder.
- A mixture of (1α,2β,3α)-1-[2-hydroxy-3-(phenylmethoxy)methyl)cyolobutyl]-2,4(1H,3H)pyrimidinedione (0.37 g, 1.22 mmol), cyclohexene (7.5 ml), and Pd(OH)2 (0.38 g, 20% on carbon) in aqueous ethanol (95%, 30 ml) was refluxed for 3 hours. After cooling, the mixture was filtered through Celite and washed well with ethanol. The residue was purified on HP20 (3 x 26 cm), eluting first with water and then a gradient of water/acetonitrile-water (1:1). The fractions containing pure compound were concentrated and the residue lyophilized to give the title compound (0.168 g) as a colorless solid. Proton NMR (400 MHz, DMSO-d6) ppm: 11.19 (broad singlet, 1 H), 7.65 (doublet, J = 8Hz, 1H), 5.61 (doublet, J = 8Hz, 1H), 5.44 (doublet, J = 6Hz, 1H), 4.52 (triplet, J = 5 Hz, 1 H), 4.39 (multiplet, 1H), 3.97 (multiplet, 1 H), 3.50 (multiplet, 2H), 2.05 (doublet of doublets, J = 9, 20Hz, 1 H), 1.91 (multiplet, 1 H), 1.35 (doublet of doublets, J = 10, 20 Hz, 1 H).
- A mixture of (1α,2β,3α)-1-[2-hydroxy-3-(hydroxymethyl)cyclobutyl]-2,4(1H,3H)-pyrimidinedione (58.1 mg, 0.275 mmol), iodine (140 mg, 0.55 mmol) and HNO3 (aqueous, 0.36 ml of 0.8N) in dioxane (6 ml, passed through basic alumina) was refluxed for 10 hours. After cooling to room temperature, the excess iodine was reduced with a minimum of solid sodium thiosulfate. The resulting mixture was purified by HP-20 (3 cm x 25 cm column), eluting with water and then a gradient of water/acetonitrile-water (1:1). The fractions containing pure compound were concentrated to give a slightly yellow solid (93 mg). This solid was recrystallized from hot water to give the title product (66 mg) as a colorless solid having m.p. 99 - 101°C.
Claims (44)
which is optionally protected and removing the protecting groups to yield a compound of formula 1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/138,737 US4855466A (en) | 1987-12-28 | 1987-12-28 | Purinyl cyclobutanes |
US138737 | 1987-12-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0322854A1 true EP0322854A1 (en) | 1989-07-05 |
EP0322854B1 EP0322854B1 (en) | 1994-07-13 |
Family
ID=22483400
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP88121712A Expired - Lifetime EP0322854B1 (en) | 1987-12-28 | 1988-12-27 | Purinyl cyclobutanes |
Country Status (25)
Country | Link |
---|---|
US (1) | US4855466A (en) |
EP (1) | EP0322854B1 (en) |
JP (1) | JP2634215B2 (en) |
KR (1) | KR970007920B1 (en) |
CN (1) | CN1032205C (en) |
AT (1) | ATE108452T1 (en) |
AU (2) | AU614105B2 (en) |
CA (1) | CA1331607C (en) |
DD (1) | DD276687A5 (en) |
DE (1) | DE3850645T2 (en) |
DK (1) | DK170340B1 (en) |
EG (1) | EG18639A (en) |
ES (1) | ES2056096T3 (en) |
FI (1) | FI90422C (en) |
HU (1) | HU203236B (en) |
IE (1) | IE64591B1 (en) |
IL (1) | IL88755A (en) |
MX (1) | MX14358A (en) |
NO (1) | NO168036C (en) |
NZ (1) | NZ227431A (en) |
PH (1) | PH25191A (en) |
PL (1) | PL159302B1 (en) |
PT (1) | PT89349B (en) |
YU (1) | YU236288A (en) |
ZA (1) | ZA889499B (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0335355A2 (en) * | 1988-03-30 | 1989-10-04 | E.R. Squibb & Sons, Inc. | Bis-(hydroxymethyl) cyclobutyl purines and pyrimidines |
EP0352013A2 (en) * | 1988-07-18 | 1990-01-24 | E.R. Squibb & Sons, Inc. | Hydroxymethyl cyclobutyl purines |
EP0366059A2 (en) | 1988-10-25 | 1990-05-02 | Bristol-Myers Squibb Company | Carbocyclic nucleoside analogs |
EP0458312A1 (en) * | 1990-05-24 | 1991-11-27 | Nippon Kayaku Kabushiki Kaisha | Novel cyclobutane derivatives |
US5153352A (en) * | 1988-10-25 | 1992-10-06 | Bristol-Myers Squibb Company | Process for preparation of intermediates of carbocyclic nucleoside analogs |
US5202459A (en) * | 1989-11-07 | 1993-04-13 | Nippon Kayaku Kabushiki Kaisha | Process for producing cyclobutane derivative |
US5214048A (en) * | 1987-05-19 | 1993-05-25 | Nippon Kayaku Kabushiki Kaisha | Oxetanocins |
EP0554025A2 (en) * | 1992-01-27 | 1993-08-04 | E.R. SQUIBB & SONS, INC. | Fluorinated cyclobutyl purines and pyrimidines |
US5235052A (en) * | 1990-04-16 | 1993-08-10 | Bristol-Myers Squibb Company | Process for preparing substituted cyclobutane purines |
US5246931A (en) * | 1988-10-25 | 1993-09-21 | Bristol-Myers Squibb Company | Carbocyclic nucleoside analogs |
EP0736533A1 (en) * | 1995-04-03 | 1996-10-09 | Bristol-Myers Squibb Company | Intermediates and process for the preparation of an antiviral agent |
US5597824A (en) * | 1987-11-03 | 1997-01-28 | Abbott Laboratories | Analogs of oxetanyl purines and pyrimidines |
US6001840A (en) * | 1990-03-06 | 1999-12-14 | Southern Research Institute | Methods of treatment of viral infections using carbocyclic deoxyguanosine analogs |
EP1828145A2 (en) * | 2004-12-10 | 2007-09-05 | Emory University | 2' and 3' - substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation |
FR3092114A1 (en) * | 2019-01-28 | 2020-07-31 | Universite Grenoble Alpes | NEW PURINE DERIVATIVES AND DRUGS CONTAINING THEM |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5126345A (en) * | 1988-03-30 | 1992-06-30 | E. R. Squibb & Sons, Inc. | Bis (hydroxymethyl) cyclobutyl triazolopyrimidines |
US5130462A (en) * | 1988-03-30 | 1992-07-14 | E. R. Squibb & Sons, Inc. | Cyclobutane derivatives |
US5185459A (en) * | 1988-03-30 | 1993-02-09 | E. R. Squibb & Sons Inc. | Bis protected (hydroxymethyl)cyclobutanols |
AU622926B2 (en) * | 1988-09-09 | 1992-04-30 | Nippon Kayaku Kabushiki Kaisha | Pyrimidine or purine cyclobutane derivatives |
US5179084A (en) * | 1989-04-10 | 1993-01-12 | Nippon Kayaku Kabushiki Kaisha | Antiviral phosphoric acid esters of oxetanocins |
NZ232993A (en) * | 1989-04-24 | 1992-10-28 | Squibb & Sons Inc | Purinyl and pyrimidinyl tetrahydrofurans |
US5164520A (en) * | 1989-04-24 | 1992-11-17 | E. R. Squibb & Sons, Inc. | Intermediates for purinyl and pyrimidinyl tetrahydrofurans |
US5059690A (en) * | 1990-03-01 | 1991-10-22 | E. R. Squibb & Sons, Inc. | Purinyl tetrahydrofurans |
US5145960A (en) * | 1989-04-24 | 1992-09-08 | E. R. Squibb & Sons, Inc. | Pyrimidinyl tetrahydrofurans |
US4988703A (en) * | 1989-05-22 | 1991-01-29 | Abbott Laboratories | Carbocyclic nucleoside analogs with antiviral activity |
US5064961A (en) * | 1989-12-18 | 1991-11-12 | E. R. Squibb & Sons, Inc. | Process for preparing an optically active cyclobutane nucleoside |
US5256806A (en) * | 1989-12-18 | 1993-10-26 | E. R. Squibb & Sons, Inc. | Intermediates for the preparation of optically active cyclobutane nucleoside |
US5198583A (en) * | 1989-12-18 | 1993-03-30 | E. R. Squibb & Sons, Inc. | Optically active cyclobutane nucleoside and intermediates, therefor |
US5233076A (en) * | 1990-05-24 | 1993-08-03 | E. R. Squibb & Sons, Inc. | Process for preparing an optically active cyclobutanone, an intermediate in the synthesis of an optically active cyclobutane nucleoside |
AU635642B2 (en) * | 1990-05-24 | 1993-03-25 | E.R. Squibb & Sons, Inc. | Fluorinated bis(hydroxymethyl) cyclobutyl purines and pyrimidines |
US5344962A (en) * | 1990-05-24 | 1994-09-06 | E. R. Squibb & Sons, Inc. | Intermediates in the synthesis of an optically active cyclobutane nucleoside |
KR20030025153A (en) * | 2001-09-19 | 2003-03-28 | 이보섭 | Derivatives of 6-substituted aminopurine with aliphatic or aromatic functional group, and cosmetics containing the same |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0160573A2 (en) * | 1984-05-02 | 1985-11-06 | Nycomed As | Pyrimidinone derivatives |
US4605659A (en) * | 1985-04-30 | 1986-08-12 | Syntex (U.S.A.) Inc. | Purinyl or pyrimidinyl substituted hydroxycyclopentane compounds useful as antivirals |
US4617304A (en) * | 1984-04-10 | 1986-10-14 | Merck & Co., Inc. | Purine derivatives |
US4636509A (en) * | 1980-07-15 | 1987-01-13 | Glaxo Group Limited | Substituted pyrimidin-2-ones, the salts thereof, processes for their preparation, pharmaceutical compositions containing them and a method therefor |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4543255A (en) * | 1984-05-10 | 1985-09-24 | Southern Research Institute | Carbocyclic analogs of purine 2'-deoxyribofuranosides |
EP0184473A1 (en) * | 1984-10-26 | 1986-06-11 | Merck & Co. Inc. | Regioselective synthesis of 9-substituted purine acyclonucleoside derivatives |
US4743689A (en) * | 1984-11-20 | 1988-05-10 | Nippon Kayaku Kabushiki Kaisha | Antibiotic derivative of adenine |
ES2001094A6 (en) * | 1985-08-16 | 1988-04-16 | Glaxo Group Ltd | Guanine derivatives. |
EP0219838A3 (en) * | 1985-10-22 | 1988-04-06 | Takeda Chemical Industries, Ltd. | Carbocyclic purine nucleosides, their production and use |
JPH0228161A (en) * | 1987-05-25 | 1990-01-30 | Nippon Kayaku Co Ltd | Novel cyclobutane derivative |
AU4378589A (en) * | 1988-10-25 | 1990-05-03 | Bristol-Myers Squibb Company | Carbocyclic nucleoside analogs |
-
1987
- 1987-12-28 US US07/138,737 patent/US4855466A/en not_active Expired - Lifetime
-
1988
- 1988-12-20 CA CA000586436A patent/CA1331607C/en not_active Expired - Fee Related
- 1988-12-20 ZA ZA889499A patent/ZA889499B/en unknown
- 1988-12-21 PH PH37962A patent/PH25191A/en unknown
- 1988-12-21 NZ NZ227431A patent/NZ227431A/en unknown
- 1988-12-21 IL IL88755A patent/IL88755A/en not_active IP Right Cessation
- 1988-12-21 IE IE382788A patent/IE64591B1/en not_active IP Right Cessation
- 1988-12-23 AU AU27470/88A patent/AU614105B2/en not_active Ceased
- 1988-12-23 FI FI885980A patent/FI90422C/en not_active IP Right Cessation
- 1988-12-27 YU YU02362/88A patent/YU236288A/en unknown
- 1988-12-27 NO NO885768A patent/NO168036C/en unknown
- 1988-12-27 DE DE3850645T patent/DE3850645T2/en not_active Expired - Fee Related
- 1988-12-27 EP EP88121712A patent/EP0322854B1/en not_active Expired - Lifetime
- 1988-12-27 KR KR1019880017570A patent/KR970007920B1/en not_active IP Right Cessation
- 1988-12-27 MX MX1435888A patent/MX14358A/en unknown
- 1988-12-27 HU HU886619A patent/HU203236B/en not_active IP Right Cessation
- 1988-12-27 AT AT88121712T patent/ATE108452T1/en not_active IP Right Cessation
- 1988-12-27 DK DK724088A patent/DK170340B1/en not_active IP Right Cessation
- 1988-12-27 ES ES88121712T patent/ES2056096T3/en not_active Expired - Lifetime
- 1988-12-28 DD DD88324295A patent/DD276687A5/en not_active IP Right Cessation
- 1988-12-28 JP JP63332693A patent/JP2634215B2/en not_active Expired - Fee Related
- 1988-12-28 PL PL1988276787A patent/PL159302B1/en unknown
- 1988-12-28 PT PT89349A patent/PT89349B/en not_active IP Right Cessation
- 1988-12-28 CN CN89101104A patent/CN1032205C/en not_active Expired - Fee Related
- 1988-12-28 EG EG660/88A patent/EG18639A/en active
-
1991
- 1991-05-31 AU AU78107/91A patent/AU633437B2/en not_active Ceased
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4636509A (en) * | 1980-07-15 | 1987-01-13 | Glaxo Group Limited | Substituted pyrimidin-2-ones, the salts thereof, processes for their preparation, pharmaceutical compositions containing them and a method therefor |
US4617304A (en) * | 1984-04-10 | 1986-10-14 | Merck & Co., Inc. | Purine derivatives |
EP0160573A2 (en) * | 1984-05-02 | 1985-11-06 | Nycomed As | Pyrimidinone derivatives |
US4605659A (en) * | 1985-04-30 | 1986-08-12 | Syntex (U.S.A.) Inc. | Purinyl or pyrimidinyl substituted hydroxycyclopentane compounds useful as antivirals |
Non-Patent Citations (1)
Title |
---|
Journal of Medicinal Chemistry, Vol. 27, No. 10, October 1984 R. VINCE et al. "Carbocyclic Analoges of Xylofuranosylpurine Nucleosides. Synthesis and Antitumor Activity." pages 1358-1360 * |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5214048A (en) * | 1987-05-19 | 1993-05-25 | Nippon Kayaku Kabushiki Kaisha | Oxetanocins |
US5597824A (en) * | 1987-11-03 | 1997-01-28 | Abbott Laboratories | Analogs of oxetanyl purines and pyrimidines |
EP0335355A2 (en) * | 1988-03-30 | 1989-10-04 | E.R. Squibb & Sons, Inc. | Bis-(hydroxymethyl) cyclobutyl purines and pyrimidines |
EP0335355B1 (en) * | 1988-03-30 | 1997-10-01 | E.R. Squibb & Sons, Inc. | Bis-(hydroxymethyl) cyclobutyl purines and pyrimidines |
EP0352013A2 (en) * | 1988-07-18 | 1990-01-24 | E.R. Squibb & Sons, Inc. | Hydroxymethyl cyclobutyl purines |
EP0352013A3 (en) * | 1988-07-18 | 1991-11-06 | E.R. Squibb & Sons, Inc. | Hydroxymethyl cyclobutyl purines |
EP0366059A2 (en) | 1988-10-25 | 1990-05-02 | Bristol-Myers Squibb Company | Carbocyclic nucleoside analogs |
US5153352A (en) * | 1988-10-25 | 1992-10-06 | Bristol-Myers Squibb Company | Process for preparation of intermediates of carbocyclic nucleoside analogs |
US5246931A (en) * | 1988-10-25 | 1993-09-21 | Bristol-Myers Squibb Company | Carbocyclic nucleoside analogs |
US5202459A (en) * | 1989-11-07 | 1993-04-13 | Nippon Kayaku Kabushiki Kaisha | Process for producing cyclobutane derivative |
US6001840A (en) * | 1990-03-06 | 1999-12-14 | Southern Research Institute | Methods of treatment of viral infections using carbocyclic deoxyguanosine analogs |
US5312963A (en) * | 1990-04-16 | 1994-05-17 | Bristol-Myers Squibb Co. | Process for preparing substituted cyclobutanes |
US5399775A (en) * | 1990-04-16 | 1995-03-21 | Bristol-Myers Squibb Co. | Process for preparing substituted cyclobutanes |
US5235052A (en) * | 1990-04-16 | 1993-08-10 | Bristol-Myers Squibb Company | Process for preparing substituted cyclobutane purines |
US5324730A (en) * | 1990-05-24 | 1994-06-28 | Nippon Kayaku Kabushiki Kaisha | Phenoxyphosphoryloxymethyl cyclobutyl purines |
EP0458312A1 (en) * | 1990-05-24 | 1991-11-27 | Nippon Kayaku Kabushiki Kaisha | Novel cyclobutane derivatives |
EP0554025A3 (en) * | 1992-01-27 | 1993-11-18 | Squibb & Sons Inc | Fluorinated cyclobutyl purines and pyrimidines |
EP0554025A2 (en) * | 1992-01-27 | 1993-08-04 | E.R. SQUIBB & SONS, INC. | Fluorinated cyclobutyl purines and pyrimidines |
US5773614A (en) * | 1995-04-03 | 1998-06-30 | Bristol-Myers Squibb Co. | Process for the preparation of an antiviral agent |
EP0736533A1 (en) * | 1995-04-03 | 1996-10-09 | Bristol-Myers Squibb Company | Intermediates and process for the preparation of an antiviral agent |
EP1828145A2 (en) * | 2004-12-10 | 2007-09-05 | Emory University | 2' and 3' - substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation |
EP1828145A4 (en) * | 2004-12-10 | 2009-08-19 | Univ Emory | 2' and 3' - substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation |
US8114994B2 (en) | 2004-12-10 | 2012-02-14 | Emory University | 2′ and 3′-substituted cyclobutyl nucleoside analogs for the treatment viral infections and abnormal cellular proliferation |
FR3092114A1 (en) * | 2019-01-28 | 2020-07-31 | Universite Grenoble Alpes | NEW PURINE DERIVATIVES AND DRUGS CONTAINING THEM |
WO2020157626A1 (en) * | 2019-01-28 | 2020-08-06 | Université Grenoble Alpes | Novel purine derivatives and drugs comprising same |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0322854B1 (en) | Purinyl cyclobutanes | |
US4918075A (en) | Purinyl and pyrimidinyl cyclobutanes and their use as antiviral agents | |
US5723609A (en) | Bis (hydroxymethyl) cyclobutyl purines | |
EP0481754B1 (en) | Hydroxymethyl(methylenecyclopentyl)Purines and Pyrimidines | |
EP0560794B1 (en) | Substituted 1,3-oxathiolanes with antiviral properties | |
US5126345A (en) | Bis (hydroxymethyl) cyclobutyl triazolopyrimidines | |
EP0608809B1 (en) | Antiviral tetrahydropyrans | |
AU635642B2 (en) | Fluorinated bis(hydroxymethyl) cyclobutyl purines and pyrimidines | |
JP3146423B2 (en) | Replacement pudding | |
CA2012851C (en) | Purinyl and pyrimidinyl tetrahydrofurans | |
US5130462A (en) | Cyclobutane derivatives | |
US5374625A (en) | Adenine and guanine derivatives for the treatment of hepatitis virus infections | |
EP0464769B1 (en) | Purinyl and pyrimidinyl tetrahydrofurans | |
EP0352013B1 (en) | Hydroxymethyl cyclobutyl purines | |
CA1339647C (en) | Bis-(hydroxymethyl) cyclobutyl purines and pyrimidines | |
EP0630897A2 (en) | 3-Hydroxy-4-hydroxymethyl-2-methylene-cyclopentyl purines and pyrimidines | |
EP0554025A2 (en) | Fluorinated cyclobutyl purines and pyrimidines | |
PH26922A (en) | Purinyl cyclobutanes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE |
|
17P | Request for examination filed |
Effective date: 19900103 |
|
17Q | First examination report despatched |
Effective date: 19911115 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE |
|
REF | Corresponds to: |
Ref document number: 108452 Country of ref document: AT Date of ref document: 19940715 Kind code of ref document: T |
|
ET | Fr: translation filed | ||
REF | Corresponds to: |
Ref document number: 3850645 Country of ref document: DE Date of ref document: 19940818 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2056096 Country of ref document: ES Kind code of ref document: T3 |
|
ITF | It: translation for a ep patent filed | ||
REG | Reference to a national code |
Ref country code: GR Ref legal event code: FG4A Free format text: 3013494 |
|
EAL | Se: european patent in force in sweden |
Ref document number: 88121712.9 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20051111 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20051204 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20051206 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20051208 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20051213 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20051221 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20051222 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20051229 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20060112 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20060118 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20060216 Year of fee payment: 18 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061228 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061231 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061231 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061231 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20061231 Year of fee payment: 19 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070701 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070703 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
EUG | Se: european patent has lapsed | ||
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20061227 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 20070701 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20070831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061227 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061227 |
|
BERE | Be: lapsed |
Owner name: E.R. *SQUIBB & SONS INC. Effective date: 20061231 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20061228 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061228 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070102 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061227 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070704 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20071227 |